BamSEC and AlphaSense Join Forces
Learn More

Quince Therapeutics Inc.

NASDAQ: QNCX    
Share price (12/20/24): $1.78    
Market cap (12/20/24): $78.3 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.27
from 10-K 19 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit in Accordance With Item 601(b)(10) of Regulation S-K Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. To: Quince Therapeutics, Inc. 601 Gateway Blvd. Suite 1250 South San Francisco, Ca 94080 USA Email Address: [***] to the Kind Attention Of: Brendan Hannah via Courier Anticipated via E-Mail
12/34/56
EX-10.26
from 10-K 83 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit in Accordance With Item 601(b)(10) of Regulation S-K Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. To: European Investment Bank 100, Boulevard Konrad Adenauer L-2950 Luxembourg Luxembourg Email Address: OPS-ENPST3-SECRETARIAT@EIB.ORG to the Kind Attention Of: Ops-Enpst3-Secretariat
12/34/56
EX-10.6
from 10-K 52 pages Quince Therapeutics, Inc. 2019 Equity Incentive Plan 1
12/34/56
EX-10.4
from 10-Q 11 pages Quince Therapeutics, Inc. Executive Change in Control and Severance Agreement
12/34/56
EX-10.3
from 10-Q 11 pages Docuslgn Envelope Id: F7c9e685-A526-42df•a1cb-6fbdc9b4648b August 1, 2023 Charles Ryan via Electronic Delivery Re: Offer of Employment With Quince Therapeutics, Inc. 1
12/34/56
EX-10.2
from 10-Q 12 pages Quince Therapeutics, Inc. July 21, 2023 1
12/34/56
EX-10.1
from 10-Q 3 pages Amendment #3 to License Agreement
12/34/56
EX-10.1
from 10-Q 39 pages Asset Purchase Agreement by and Between Quince Therapeutics, Inc. and Lighthouse Pharmaceuticals, Inc. Dated January 27, 2023
12/34/56
EX-10.1
from 10-Q 6 pages Amendment #2 to License Agreement
12/34/56
EX-10.19
from 10-Q 9 pages Amendment #1 to License Agreement
12/34/56
EX-10.18
from 10-Q 23 pages License Agreement
12/34/56
EX-10.17
from 10-Q 3 pages Cortexyme, Inc. Outside Director Compensation Policy Adopted: April 9, 2019; Amended and Restated: June 7, 2022 Effective: May 8, 2019 (The “Effective Date”) Annual Cash Compensation
12/34/56
EX-10.16
from 10-Q 7 pages Cortexyme, Inc
12/34/56
EX-10.15
from 10-Q 5 pages Consent to Sublease
12/34/56
EX-10.14
from 10-Q 13 pages Sublease Agreement
12/34/56
EX-10.13
from 10-Q 17 pages Cortexyme, Inc
12/34/56
EX-10.12
from 10-Q 9 pages Cortexyme, Inc. Executive Change in Control and Severance Agreement
12/34/56
EX-10.11
from 10-Q 10 pages Cortexyme, Inc. Executive Change in Control and Severance Agreement
12/34/56
EX-10.10
from 10-Q 11 pages Cortexyme, Inc. Executive Change in Control and Severance Agreement
12/34/56
EX-10.9
from 10-Q 23 pages Cortexyme, Inc
12/34/56